Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11.4mln.
Lowi says the R&D collaboration with Bach is a very exiting step, potentially leading to a pre-clinical deal with big pharma in the next 12-18 month.
On Avacta's fundraise, he says the move should support operations well into calendar year 2020.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE